Japanese drug kingpin Takeda mulling approach for Shire
Any deal would likely bid Irish rare disease specialist at close to €57bn
Any deal would likely bid Irish rare disease specialist at close to €57bn
Firm planning to create 150 new jobs in State reports product sales up 110% to $3.4bn
Irish-domiciled business says cost savings in $32bn Baxalta deal 40% more than expected
Iseq also falls with Ryanair and Dalata down and Kingspan one of the only risers
Number of mergers and acquisitions up 10%, from 416 to 458 deals
Shire shares slide 8% as analysts concerned about ambitious savings target from merger
Inversion deal will see Baxalta cut its tax rate from 23% to 16%
If deal goes ahead , enlarged company would generate $20 billion in sales by 2020
Shire has been pursuing Illinois-headquartered Baxalta for the past five months
CEO Flemming Ornskov refused to be drawn on whether drugmaker will pitch new higher offer
Shire CEO confident Baxalta shareholders are open to a deal
Investor says shareholders in Dublin company may back increase from current $45.23 a share offer to $50 but some unease over scale of acquisition
Dublin-based group went public with its approach after the US firm turned it down
Shire, Barclays, Credit Agricole and Lufthansa among the losers
Crosswords & puzzles to keep you challenged and entertained
Full general election coverage including analysis and results for all 43 constituencies
How does a post-Brexit world shape the identity and relationship of these islands
Weddings, Births, Deaths and other family notices